Assembly Biosciences Q3 net loss narrows, raises $175 mln

Assembly Biosciences

10/11/2025 21:26

Overview

Assembly Biosciences Q3 net loss narrows to $9.2 mln, EPS at -$0.72

Company raised $175 mln from equity financing to support clinical developments

Positive Phase 1b results for ABI-5366 show reduced viral shedding in genital herpes

Outlook

Company expects interim Phase 1b HSV data by year-end

Company plans to initiate Phase 2 study of ABI-5366 in mid-2026

Assembly Bio's cash position projected to fund operations into late 2027

Result Drivers

REVENUE - Revenue from collaborative research with Gilead rose to $10.8 mln from $6.8 mln, reflecting increased research and development incurred under the collaboration as well as an increase in collaboration funding

R&D EXPENSES - Costs rose due to increase in spending on the company's HSV program

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.72
Q3 Net Income
-$9.20 mln
Q3 Basic EPS
-$0.72
Q3 Income From Operations
-$10.88 mln
Q3 Operating Expenses
$21.67 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Assembly Biosciences Inc is $38.00, about 17.9% above its November 7 closing price of $31.20

Press Release: ID:nGNX8lDbfM

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)